非奈利酮用于糖尿病肾病药学实践并文献分析  

Pharmaceutical Practice and Literature Analysis of Finerenone for Diabetic Nephropathy

作　　者：曹馨月 曹伟灵[2] 朱丹华[2] 郑桂梅 CAO Xinyue;CAO Weiling;ZHU Danhua;ZHENG Guimei(South China Hospital of Shenzhen University,Shenzhen,Guangdong,China 518111;Luohu People's Hospital,Shenzhen,Guangdong,China 518000)

机构地区：[1]深圳大学附属华南医院,广东深圳518111 [2]广东省深圳市罗湖区人民医院,广东深圳518000

出　　处：《中国药业》2024年第18期120-125,共6页China Pharmaceuticals

基　　金：广东省医院协会药学科研专项基金[2022YSGL04];广东省深圳市罗湖区人民医院临床研究项目[LCYJ202203]。

摘　　要：目的 促进非奈利酮在糖尿病肾病患者中的合理使用。方法 针对深圳市罗湖区人民医院收治的1例糖尿病肾病患者的大量白蛋白尿症状,药师会诊中检索国内外关于非奈利酮的文献报道,协助医师制订及调整药物治疗方案,并于患者入院第4天根据具体情况建议加用非奈利酮(10 mg,每日1次,口服)。结果 医师采纳临床药师用药建议,患者的大量白蛋白尿及低血钾等其他症状得到有效改善。入院第10天,患者血糖控制尚可,乏力及下肢水肿较前好转,后出院。结论 临床药师通过分析病情及查阅文献参与药学监护,可确保糖尿病肾病患者药物治疗的有效性和安全性,也有助于非奈利酮在该病中的正确、合理使用。Objective To promote the rational use of finerenone in patients with diabetic nephropathy.Methods For the massive proteinuria in a patient with diabetic nephropathy admitted to Luohu People's Hospital,the pharmacists assisted physicians to formulate and adjust the treatment regimens based on the domestic and foreign literature on finerenone,and suggested the addition of finerenone(10 mg,once a day,oral)according to the patient's disease condition on the fourth day of admission.Results The physicians adopted the medication suggestions of the clinical pharmacists,and the patient's conditions such as massive proteinuria and hypokalemia effectively improved.On the 10th day of admission,the patient's blood glucose was well controlled,his weakness and lower limb edema improved,and then he successfully discharged from the hospital.Conclusion Clinical pharmacists'participation in the pharmaceutical care based on disease analysis and literature review can ensure the effectiveness and safety of drug treatment for patients with diabetic nephropathy,and also promote the correct and rational use of finerenone in the treatment of this disease.

关 键 词：非奈利酮 糖尿病肾病 白蛋白尿 心肾结局 血钾 

分 类 号：R963[医药卫生—微生物与生化药学] R587.2[医药卫生—药理学]